{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-08-07",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 2
    }
  },
  "results": [
    {
      "submissions": [
        {
          "submission_type": "SUPPL",
          "submission_number": "1",
          "submission_status": "AP",
          "submission_status_date": "20011011",
          "review_priority": "STANDARD",
          "submission_class_code": "EFFICACY",
          "submission_class_code_description": "Efficacy",
          "application_docs": [
            {
              "id": "42010",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-184S001_Tazorac.html",
              "date": "20011212",
              "type": "Review"
            },
            {
              "id": "4595",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2001/21184s1ltr.pdf",
              "date": "20011024",
              "type": "Letter"
            },
            {
              "id": "14604",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21184s1lbl.pdf",
              "date": "20011024",
              "type": "Label"
            }
          ]
        },
        {
          "submission_type": "SUPPL",
          "submission_number": "8",
          "submission_status": "AP",
          "submission_status_date": "20160916",
          "submission_public_notes": "Avage label updated",
          "review_priority": "STANDARD",
          "submission_class_code": "LABELING",
          "submission_class_code_description": "Labeling",
          "application_docs": [
            {
              "id": "45315",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021184s008lbl.pdf",
              "date": "20160916",
              "type": "Label"
            },
            {
              "id": "45350",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/021184Orig1s008ltr.pdf",
              "date": "20161109",
              "type": "Letter"
            }
          ]
        },
        {
          "submission_type": "SUPPL",
          "submission_number": "2",
          "submission_status": "AP",
          "submission_status_date": "20020930",
          "review_priority": "STANDARD",
          "submission_class_code": "EFFICACY",
          "submission_class_code_description": "Efficacy",
          "application_docs": [
            {
              "id": "14605",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21184s2lbl.pdf",
              "date": "20040527",
              "type": "Label"
            },
            {
              "id": "21497",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-184s002_Avage.html",
              "date": "20040115",
              "type": "Review"
            },
            {
              "id": "27021",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/21184se1-002ltr.pdf",
              "date": "20040527",
              "type": "Letter"
            }
          ]
        },
        {
          "submission_type": "SUPPL",
          "submission_number": "9",
          "submission_status": "AP",
          "submission_status_date": "20170721",
          "submission_public_notes": "Label for Avage and Tazorac",
          "review_priority": "STANDARD",
          "submission_class_code": "LABELING",
          "submission_class_code_description": "Labeling",
          "application_docs": [
            {
              "id": "49052",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021184s009lbl.pdf",
              "date": "20170725",
              "type": "Label"
            },
            {
              "id": "49076",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/021184Orig1s009,020600Orig1s009ltr.pdf",
              "date": "20170725",
              "type": "Letter"
            }
          ]
        },
        {
          "submission_type": "ORIG",
          "submission_number": "1",
          "submission_status": "AP",
          "submission_status_date": "20000929",
          "review_priority": "STANDARD",
          "submission_class_code": "TYPE 3",
          "submission_class_code_description": "Type 3 - New Dosage Form",
          "application_docs": [
            {
              "id": "42009",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-184_Tazorac.html",
              "date": "20040328",
              "type": "Review"
            },
            {
              "id": "27020",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2000/21184ltr.pdf",
              "date": "20000929",
              "type": "Letter"
            },
            {
              "id": "36313",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21184lbl.pdf",
              "date": "20000929",
              "type": "Label"
            }
          ]
        },
        {
          "submission_type": "SUPPL",
          "submission_number": "7",
          "submission_status": "AP",
          "submission_status_date": "20131213",
          "submission_public_notes": "Tazorac label updated",
          "review_priority": "STANDARD",
          "submission_class_code": "LABELING",
          "submission_class_code_description": "Labeling",
          "application_docs": [
            {
              "id": "14606",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021184s007lbl.pdf",
              "date": "20131217",
              "type": "Label"
            },
            {
              "id": "27022",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/021184Orig1s007ltr.pdf",
              "date": "20131217",
              "type": "Letter"
            }
          ]
        }
      ],
      "application_number": "NDA021184",
      "sponsor_name": "ALMIRALL",
      "openfda": {
        "application_number": [
          "NDA021184"
        ],
        "brand_name": [
          "TAZORAC"
        ],
        "generic_name": [
          "TAZAROTENE"
        ],
        "manufacturer_name": [
          "Almirall, LLC"
        ],
        "product_ndc": [
          "16110-915",
          "16110-916"
        ],
        "product_type": [
          "HUMAN PRESCRIPTION DRUG"
        ],
        "route": [
          "CUTANEOUS"
        ],
        "substance_name": [
          "TAZAROTENE"
        ],
        "spl_id": [
          "ee97b76e-eb11-4165-ae85-1277eba9ff35"
        ],
        "spl_set_id": [
          "021744d1-a6d7-4ad6-99c2-7187c24e64c6"
        ],
        "package_ndc": [
          "16110-915-30",
          "16110-915-60",
          "16110-916-30",
          "16110-916-60"
        ],
        "nui": [
          "N0000175607",
          "M0018962"
        ],
        "pharm_class_epc": [
          "Retinoid [EPC]"
        ],
        "pharm_class_cs": [
          "Retinoids [CS]"
        ],
        "unii": [
          "81BDR9Y8PS"
        ]
      },
      "products": [
        {
          "product_number": "002",
          "reference_drug": "Yes",
          "brand_name": "TAZORAC",
          "active_ingredients": [
            {
              "name": "TAZAROTENE",
              "strength": "0.1%"
            }
          ],
          "reference_standard": "Yes",
          "dosage_form": "CREAM",
          "route": "TOPICAL",
          "marketing_status": "Prescription",
          "te_code": "AB"
        },
        {
          "product_number": "003",
          "reference_drug": "Yes",
          "brand_name": "AVAGE",
          "active_ingredients": [
            {
              "name": "TAZAROTENE",
              "strength": "0.1%"
            }
          ],
          "reference_standard": "Yes",
          "dosage_form": "CREAM",
          "route": "TOPICAL",
          "marketing_status": "Prescription",
          "te_code": "AB"
        },
        {
          "product_number": "001",
          "reference_drug": "Yes",
          "brand_name": "TAZORAC",
          "active_ingredients": [
            {
              "name": "TAZAROTENE",
              "strength": "0.05%"
            }
          ],
          "reference_standard": "Yes",
          "dosage_form": "CREAM",
          "route": "TOPICAL",
          "marketing_status": "Prescription",
          "te_code": "AB"
        }
      ]
    }
  ]
}